Ref: F.No.:49 June 30, 2020 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Earnings Presentation for Quarter 4 – Financial Year 2019-2020 / Financial Year 2019-2020 Ref: Scrip Code: 506414 Further to our intimation regarding approval of Audited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and financial year ended March 31, 2020, we hereby enclose a copy of Earnings Presentation for Quarter 4 – Financial Year 2019-2020 / Financial Year 2019-2020. The said Earnings Presentation is also available on Company’s website www.fermentabiotech.com Kindly take the same on record. Thanking you, Yours faithfully, for Fermenta Biotech Limited [Formerly known as DIL LIMITED] Srikant N Sharma Company Secretary CS Membership No: F3617 A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610 Encl: As above
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Ref: F.No.:49
June 30, 2020
Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Earnings Presentation for Quarter 4 – Financial Year 2019-2020 / Financial Year
2019-2020
Ref: Scrip Code: 506414
Further to our intimation regarding approval of Audited Financial Results (Standalone and Consolidated) by the
Board of Directors for the quarter and financial year ended March 31, 2020, we hereby enclose a copy of
Earnings Presentation for Quarter 4 – Financial Year 2019-2020 / Financial Year 2019-2020.
The said Earnings Presentation is also available on Company’s website www.fermentabiotech.com
Kindly take the same on record. Thanking you, Yours faithfully, for Fermenta Biotech Limited [Formerly known as DIL LIMITED] Srikant N Sharma Company Secretary CS Membership No: F3617 A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610 Encl: As above
Earnings Presentation | Q4-FY20 / FY20
Fermenta Biotech Limited 2
Snapshot
Global Presence in 50+ countries
8 new patents filed
Only manufacturer of Vitamin D3 in India
Amongst top 3 manufacturers of Vitamin D3 globally
Top
3
Proprietary technology to manufacture Vitamin D3
50 Years of Vitamin D3 manufacturing experience
2 Manufacturing Plants registered with US-FDA (FFRM)
DSIR approved R&D facility
Big 4 Statutory Auditor with Deloitte
300+ clients across the globe Backward integrated High Return Ratios
Fermenta Biotech Limited 3
Company Overview• Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is
engaged in development and manufacturing of pharmaceuticals, biotechnology andenvironmental solutions used across various industries.
• On September 26, 2019, NCLT approved amalgamation of DIL & FBL which consolidated FBL'sleadership capabilities backed by DIL’s large asset base.
• With a rich history of six decades FBL has evolved as a key global player in manufacturing ofVitamin D3 in all its formats.
• FBL manufactures a range of Vitamin D3 variants having an optimal mix between human andanimal feed products which have applications across multiple sectors like:
• The company is also involved in manufacturing of APIs for muscle relaxant andanti-flatulent applications.
• FBL delivers innovative enzymes used in manufacturing of antibiotics and involved inenvironmental solutions used for waste water treatment and management.
• The company also has legacy properties at Thane and Worli in Mumbai for which it realizessignificant rental income.
o In Compliance with the directions issued by the Government of India, the Company had suspended operations at all of its manufacturinglocations in Dahej, Gujarat and Kullu, Himachal Pradesh with effect from 25th March 2020 to ensure the safety of its employees and theirfamilies and to contain the spread of COVID-19.
o The Company was granted permission by the District Magistrate, to partially run both of its plants, for manufacturing of EssentialCommodities. In view of the same, the Company resumed partial operations at Kullu plant from 3rd April 2020 and Dahej plant from 4thApril 2020.
o As per the current assessment of the situation based on the internal and external information the Company believes that the Impact ofCovid-19 on its business would be limited and there is no indication of any material Impact on the financials.
• The prices of Vitamin D3 Animal Feed saw some strengthening in Q1-FY21 after being under pressure for the earlier 6 months.
• The Company has embarked on a capex of around INR 300 Mn at its Dahej plant to be 80% financed through foreign currency term loan forconstruction of multi-synthesis plant, with the balance 20% to be financed through internal accruals.
• The company also completed successful production of cholesterol from fish oil through third party contract manufacturing in Q4-FY20. Theexport sales of the same has also already commenced.
• The company has a non-China dependent supply chain.
• Lastly, the Company opened a wholly owned USA subsidiary on May 27, 2020 in the name of Fermenta Biotech USA LLC to facilitate exports andenhance Company’s business in North America.
DisclaimerNo representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation.Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forwardlooking statements" based on the currently held beliefs and assumptions of the management Fermenta Biotech Limited (“Company” or “FBL”), which are expressed in good faith and in their opinion reasonable,including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatoryenvironment.
Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry resultsto differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business,its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of thispresentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events ordevelopments.
This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offeror invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contractor commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to anexemption from registration there from.
This presentation is confidential andmay not be copied or disseminated, in whole or in part, and in any manner.
ValoremAdvisors Disclaimer:Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable,but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of thecontents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, thisPresentation is expressly excluded. ValoremAdvisors also hereby certifies that the directors or employees of ValoremAdvisors do not own any stock in personal or company capacity of the Company under review.
For further information please contact our Investor Relations Representatives:Mr. Anuj SonpalValorem AdvisorsTel: +91-22-4903-9500Email: [email protected]